Developing African arbovirus networks and capacity strengthening in arbovirus surveillance and response: findings from a virtual workshop.


Journal

Parasites & vectors
ISSN: 1756-3305
Titre abrégé: Parasit Vectors
Pays: England
ID NLM: 101462774

Informations de publication

Date de publication:
14 Apr 2023
Historique:
received: 16 01 2023
accepted: 18 03 2023
medline: 18 4 2023
entrez: 14 4 2023
pubmed: 15 4 2023
Statut: epublish

Résumé

This meeting report presents the key findings and discussion points of a 3-h virtual workshop, held on 21 September 2022, and organized by the "Resilience Against Future Threats through Vector Control (RAFT)" research consortium. The workshop aimed to identify priorities for advancing arbovirus research, network and capacity strengthening in Africa. Due to increasing human population growth, urbanization and global movement (trade, tourism, travel), mosquito-borne arboviral diseases, such as dengue, Chikungunya and Zika, are increasing globally in their distribution and prevalence. This report summarizes the presentations that reviewed the current status of arboviruses in Africa, including: (i) key findings from the recent WHO/Special Programme for Research & Training in Tropical Diseases (WHO/TDR) survey in 47 African countries that revealed deep and widespread shortfalls in the capacity to cope with arbovirus outbreak preparedness, surveillance and control; (ii) the value of networking in this context, with examples of African countries regarding arbovirus surveillance; and (iii) the main priorities identified by the breakout groups on "research gaps", "networks" and "capacity strengthening".

Identifiants

pubmed: 37059998
doi: 10.1186/s13071-023-05748-7
pii: 10.1186/s13071-023-05748-7
pmc: PMC10103543
doi:

Types de publication

Congress Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

129

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

© 2023. The Author(s).

Références

PLoS Negl Trop Dis. 2017 Sep 22;11(9):e0005961
pubmed: 28937986
Nature. 2013 Apr 25;496(7446):504-7
pubmed: 23563266
Lancet Microbe. 2022 Jun;3(6):e407
pubmed: 35659901
Emerg Infect Dis. 2012 Feb;18(2):318-21
pubmed: 22305525
Lancet Infect Dis. 2016 Aug;16(8):935-41
pubmed: 27091092
Lancet Infect Dis. 2016 Jun;16(6):712-723
pubmed: 26874619
Emerg Infect Dis. 2012 Dec;18(12):2051-4
pubmed: 23171668
Sci Rep. 2022 May 10;12(1):7616
pubmed: 35538241
Emerg Infect Dis. 2015 Dec;21(12):2225-9
pubmed: 26583836
PLoS Negl Trop Dis. 2016 Feb 24;10(2):e0004466
pubmed: 26910907

Auteurs

Leo Braack (L)

Malaria Consortium Asia, Bangkok, Thailand. l.braack@malariaconsortium.org.

Shobiechah A Wulandhari (SA)

Malaria Consortium Asia, Bangkok, Thailand.

Emmanuel Chanda (E)

WHO Regional Office for Africa, Brazzaville, Congo.

Florence Fouque (F)

WHO Special Programme for Research & Training in Tropical Diseases (TDR), Geneva, Switzerland.

Corinne S Merle (CS)

WHO Special Programme for Research & Training in Tropical Diseases (TDR), Geneva, Switzerland.

Udoka Nwangwu (U)

National Arbovirus & Vectors Research Centre (NAVRC), Enugu, Nigeria.

Raman Velayudhan (R)

Department for the Control of Neglected Tropical Diseases, WHO, Geneva, Switzerland.

Marietjie Venter (M)

Zoonotic Arbo- and Respiratory Virus Research Programme, Department of Medical Virology, University of Pretoria, Pretoria, South Africa.

A Gildas Yahouedo (AG)

WHO Special Programme for Research & Training in Tropical Diseases (TDR), Geneva, Switzerland.

Jo Lines (J)

Department of Disease Control, London School of Hygiene & Tropical Medicine, London, UK.

Poe Poe Aung (PP)

Malaria Consortium Asia, Bangkok, Thailand.

Kallista Chan (K)

Department of Disease Control, London School of Hygiene & Tropical Medicine, London, UK.

Tarakegn A Abeku (TA)

Malaria Consortium, London, UK.

James Tibenderana (J)

Malaria Consortium, London, UK.

Sian E Clarke (SE)

Department of Disease Control, London School of Hygiene & Tropical Medicine, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH